International Breast Cancer Day: From Awareness to Accountable Action

1School of Medicine, Universidad de Buenos Aires (UBA); Emeritus Member of ASCO and ESMO; Honorary
Member of the Argentine Medical Association (AMA), Argentina

Received Date: 17 October 2025; Accepted Date: 22 October 2025; Published Date: 29 October 2025

*Correspondence Address: School of Medicine, Universidad de Buenos Aires (UBA); Emeritus Member of ASCO
and ESMO; Honorary Member of the Argentine Medical Association (AMA), Argentina.

Copyright©2025 by Adrián P. Hunis. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract

Background: Breast cancer is the most commonly diagnosed malignancy in women worldwide and a leading cause of cancer death [1,2]. Beyond its biological heterogeneity, it reflects deep social inequities [3].
Objective: To synthesize epidemiology, public health impact, disparities across the care continuum, and the respective roles of the State, clinicians, and patients.
Methods: Narrative review of global data and major guidelines, highlighting pragmatic frameworks for prevention, early detection, and treatment [1,4-6].
Results: Incidence continues to rise in many regions, while mortality is plateauing or decreasing where screening and timely multimodal therapy are accessible [2,6-9]. Persistent gaps in access to mammography, pathology, systemic therapy, and radiotherapy contribute to avoidable deaths, particularly in low‑ and middle‑income countries (LMICs)
[3].
Conclusions: International Breast Cancer Day should move beyond symbolic awareness toward measurable coverage of quality screening, timely diagnosis, and evidence‑based treatment anchored in national cancer control plans, equitable financing, and community‑engaged care [4].

Keywords: Breast cancer, Radiotherapy, Oncology and Mammography.

Introduction

Breast Cancer as a Public Health Problem

Breast cancer (BC) concentrates a unique blend of high prevalence, protracted survivorship, and substantial economic and psychosocial tolls [1-3]. It challenges health systems through needs that span decades: screening infrastructure, rapid diagnostic pathways, precision pathology, surgery, systemic therapies, and radiotherapy [5,6,10]. Because many women are diagnosed during economically productive years, BC compromises households and national productivity. Therefore, BC control is not a boutique oncology objective; it is a core public good [3]. International Breast Cancer Day invites governments and societies to translate empathy into budgets, metrics, and accountability [4]. Epidemiology of Breast Cancer Worldwide: Incidence and Mortality Globally, BC accounts for roughly one in four incident cancers in women [1,2].

Incidence is highest in the high‑income countries (HICs), driven by reproductive and lifestyle factors, while mortality is disproportionately high in LMICs owing to delayed diagnosis and constrained access to optimal therapy [3]. Subtypes matter hormone receptor positive/HER2‑negative remains the majority; triple‑negative breast cancer (TNBC) is less frequent but more aggressive [10,11]. Population aging, urbanization, obesity, and declining fertility sustain upward pressure on incidence [2]. Where organized screening and guideline‑concordant therapy expanded, mortality declined [6-9].

Table 1: Figures reflect recent global estimates; within‑region heterogeneity is substantial.
Country‑level registries and GLOBOCAN provide precise values for planning.

Disparities in Access to Prevention, Diagnosis, and Treatment

Inequity is the most remediable driver of BC mortality [3]. Delays occur at three levels: patient (awareness, costs, stigma), provider (training, guideline adherence), and system (financing, procurement, supply chains). Screening often concentrates in urban centers; pathology may be slow or inaccurate; staging imaging and radiotherapy may be unavailable [5,6,12]. Financial toxicity affects adherence across all settings [13]. Indigenous peoples, migrants, and rural communities face compounded barriers [2]. Closing these gaps rather than marginal gains in drugs alone offers the largest lives‑saved dividend [2,3].

The Role of the State

Governments must operationalize National Cancer Control Plans (NCCPs) [3,4]. Financing reforms should cap out‑of‑pocket spending and secure pooled procurement of high‑value generics and biosimilars [12].

Transparent registries and dashboards should track coverage (screening uptake, time to diagnosis, time to first treatment) and outcomes (stage distribution, survival) [4]. Public–private partnerships can expand imaging, radiotherapy, and workforce training, provided equity targets and quality standards are enforced [6].

The Role of Physicians

Clinicians translate policy into survival. Primary care providers and gynecologists normalize breast health, triage symptoms, and ensure swift referral [5,6]. Radiologists and pathologists anchor correct staging and subtyping [14,15]. Surgeons, medical oncologists, and radiation oncologists deliver curative intent care [6,9,10]. Adherence to evidence‑based guidelines, multidisciplinary tumor boards, and timely treatment initiation are modifiable determinants of survival [5,6]. Physicians should also advocate for equitable access, detect and mitigate financial toxicity [14], and support shared decision‑making sensitive to culture and language [3].

The Role of Patients
Informed patients expedite diagnosis and improve adherence [3,4]. Communities and survivors are powerful co‑designers of services from screening calendars to survivorship clinics [4]. Health literacy, peer support, and digital tools reduce missed appointments and treatment interruptions [3,4].

Prevention Plans and Campaigns

Prevention spans risk reduction and secondary prevention via early detection [3,4]. Awareness months catalyze attention, but sustained programs with measurable targets change outcomes [3]. Vaccination against HPV and HBV addresses other female cancers and liver cancers, aligning comprehensive  women’s health agendas [4].

Value of Mammography: How, When, and Where?

Mammography remains the cornerstone of early detection [6-9]. Digital mammography and increasingly tomosynthesis improves detection [22,23]. For guidelines average‑risk women, major endorse [5,6,8,16]. starting at age 40 High‑risk women require earlier initiation and MRI [5]. Quality matters: double reading or AI‑assisted triage, prompt recall pathways, and same‑day diagnostic work‑up minimize anxiety and loss to follow‑up [14].

Table 2: Mobile mammography, task‑sharing in radiology, and centralized QA enable equitable expansion, especially in rural and peri‑urban areas. Where resources are limited, early‑diagnosis pathways (rapid clinical evaluation of symptomatic women) can precede population screening while capacity scales.

Future-plans

Looking ahead, three levers can shift outcomes are the coverage, speed, and precision [3-5]. AI decision support can prioritize recalls, telepathology can lift diagnostic quality, and outcome‑based procurement can sustain access to the high‑value medicines [12]. Selected recent therapeutic advances include trastuzumab deruxtecan (DESTINY‑Breast03/04 [17,18]), T‑DM1 (KATHERINE [19]), abemaciclib (monarchE [20]), CDK4/6 inhibitors (PALOMA/MONALEESA/MONARCH [21]), and pembrolizumab in TNBC (KEYNOTE‑522/355 [22,23]).

Table 3: Selected recent therapeutic advances by subtype.

Figure 1: Early‑diagnosis pathway from symptom or abnormal screen to treatment (21‑30‑day target milestone). Current State of Breast Cancer Diagnosis, Treatment, and Theranostics.

Figure 2: Global cancer statistics 2024.
GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers.

Conclusion

International Breast Cancer Day should be judged not by pink saturation but by coverage, speed, and outcomes [3,4]. Countries can halve late‑stage presentation with organized early‑diagnosis pathways, guarantee biomarker‑driven procurement, and protect households from catastrophic costs [3,12]. Clinicians must close the gap between guidelines and delivery, and patients must be empowered partners [5,6].

Our common metric is lives saved measured transparently and improved continuously therapy  through pooled [4].

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
2. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):5-36.
3. Anderson BO, Ilbawi AM, El Saghir NS, Hancke K, Jeronimo J, Ginsburg O, et al. Optimizing breast cancer control in LMICs. Lancet Oncol. 2021;22(11):e471-e482.
4. World Health Organization. Global Breast Cancer Initiative (GBCI): Framework for action. Geneva: WHO;2021.
5. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2025.
6. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194-220.
7. International Agency for Research on Cancer (IARC). GLOBOCAN 2024 update. Data portal.
8. US Preventive Services Task Force. Screening for breast cancer: Recommendation statement. Jama.
2024;331(20):1910-8.
9. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Effects of radiotherapy and surgery on recurrence and 15-year survival. Lancet. 2011;378:1707-16.
10. Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, et al. De-escalating and escalating treatments for early breast cancer: St Gallen 2023. Ann Oncol. 2023;34(1):15-26.
11. Cortes J and Rugo HS. Pembrolizumab for PD-L1+ metastatic triple-negative breast cancer (KEYNOTE
355). N Engl J Med. 2020;382:810-21.
12. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. NCCN Guidelines Insights: Breast Cancer, 2024-2025. J Natl Compr Canc Netw. 2025;23(2):xxx-xxx.
13. Jagsi R, Ward KC, Abrahamse P, Lee KL, Hamilton AS, Graff JJ, et al. Financial toxicity and treatment nonadherence in breast cancer. J Clin Oncol. 2018;36(22):2105-12.
14. Miglioretti DL, Sprague BL, Conant EF, Kerlikowske K, Smith RA, Carney PA, et al. Breast density,
tomosynthesis, and screening performance. Radiology. 2019;291(3):640-8.
15. Pace LE and Keating NL. A systematic assessment of benefits and risk to guide breast cancer careening decisions. Jama. 2014;311(13):1327-35.
16. Oeffinger KC, Fontham ETH, Etzioni R, Herzig A, Michaelson JS, Shih YC, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. Jama.
2015;314(15):1599-614.
17. Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan vs T-DM1 in HER2+ metastatic breast cancer (DESTINY-Breast03). N Engl J Med. 2022;386:1143-54.
18. Modi S, Gambhire D, Cameron D. Trastuzumab deruxtecan in HER2-low breast cancer. Replay. N Engl J Med. 2022;387:1145-6.
19. Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617-28.
20. Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao Z, et al. Abemaciclib in high-risk early HR+ breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987-98.
21. Turner NC, Slamon DJ, Finn RS, Sledge GW, Cristofanilli M, Im SA, et al. PALOMA, MONALEESA, and MONARCH programs: collective evidence for CDK4/6 inhibitors. Various journals. 2015-23.
22. Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, et al. Pembrolizumab in early triple-negative breast cancer. N Engl J Med. 2020;382:810-21.
23. Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. The Lancet. 2020;396(10265):1817-28.